ClinicalTrials.gg

Program

olezarsen

Also written as “Olezarsen”, “Cyclosporine Capsules USP (Modified) 100 mg” and “ISIS 678354”.

Its studies are mostly in Hypertriglyceridemia, led by 2 companies.

Furthest: phase 3, since Sep 23, 202013 company-led studies, 4 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ionis Pharmaceuticals114 open or runningphase 3since Sep 23, 2020Dec 1, 2017Mar 2027phase 3 · NCT05681351
Panacea Biotec20 open or runningno phasesince Mar 2, 2010Mar 2, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2010First studies: 2 no phase studies in Healthy VolunteersNew to Panacea BiotecPanacea Biotec · NCT01080586, NCT01080560
  2. Dec 1, 2017Ionis Pharmaceuticals's first study: phase 2 study in HypertriglyceridemiaNew to Ionis PharmaceuticalsIonis Pharmaceuticals · NCT03385239 · 114 enrolled · United States, Canada
  3. Sep 23, 2020Phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT04568434 · 66 enrolled · United States, Canada, France and more
  4. Oct 4, 2021Phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05079919 · 617 enrolled · United States, Australia, Bulgaria and more
  5. Nov 11, 20212 phase 3 studies in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT05130450, NCT05185843
  6. Apr 26, 2022Phase 2 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05355402 · 154 enrolled · United States, Canada
  7. Sep 20, 2022Phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05552326 · 446 enrolled · United States, Argentina, Belgium and more
  8. Oct 11, 2022Phase 1 study in Healthy ParticipantsIonis Pharmaceuticals · NCT05579860 · 104 enrolled · United States
  9. Nov 2, 2022Phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05610280 · 1,478 enrolled · United States, Bulgaria, Canada and more
  10. Dec 25, 2022Phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05681351 · 885 enrolled · United States, Argentina, Australia and more
  11. Jul 10, 2026Phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT07727538 · 12 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 3 study in HypertriglyceridemiaIonis Pharmaceuticals · NCT05681351
  2. Jun 2027Primary completion: phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT05185843
  3. Feb 2028Primary completion: phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT05130450
  4. Aug 2030Primary completion: phase 3 study in Familial hyperchylomicronemia syndromeIonis Pharmaceuticals · NCT07727538

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07727538Familial hyperchylomicronemia syndrome · United States3RecruitingIonis PharmaceuticalsAug 203012
NCT05681351Hypertriglyceridemia · United States, Argentina, Australia and more3Active, not recruitingIonis PharmaceuticalsMar 2027885
NCT05610280Hypertriglyceridemia · United States, Bulgaria, Canada and more3CompletedIonis PharmaceuticalsAug 8, 20241,478
NCT05579860Healthy Participants · United States1CompletedIonis PharmaceuticalsMay 22, 2023104
NCT05552326Hypertriglyceridemia · United States, Argentina, Belgium and more3CompletedIonis PharmaceuticalsDec 17, 2024446
NCT05355402Hypertriglyceridemia · United States, Canada2CompletedIonis PharmaceuticalsMar 22, 2023154
NCT05185843Familial hyperchylomicronemia syndrome · United States, Canada, Sweden3Active, not recruitingIonis PharmaceuticalsJun 202724
NCT05130450Familial hyperchylomicronemia syndrome · United States, Canada, France and more3Active, not recruitingIonis PharmaceuticalsFeb 202860
NCT05079919Hypertriglyceridemia · United States, Australia, Bulgaria and more3CompletedIonis PharmaceuticalsOct 22, 2024617
NCT04568434Familial hyperchylomicronemia syndrome · United States, Canada, France and more3CompletedIonis PharmaceuticalsJul 14, 202366
NCT03385239Hypertriglyceridemia · United States, Canada2CompletedIonis PharmaceuticalsNov 25, 2019114
NCT01080586Healthy Volunteers · India–CompletedPanacea BiotecSep 200736
NCT01080560Healthy Volunteers · India–CompletedPanacea BiotecSep 200736

How it is read

Names in the registry

  • “Olezarsen”, 10 entries
  • “Cyclosporine Capsules USP (Modified) 100 mg”, 2 entries
  • “ISIS 678354”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.